Qian Qin, M.D. Titles and Appointments Assistant Professor Endowed Title Eugene P. Frenkel, M.D. Scholar in Clinical Medicine School Medical School Department Internal Medicine You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Qian Qin, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology and Oncology. She specializes in bladder, kidney, prostate, and testicular cancer. I really enjoy taking part in the multidisciplinary, patient-centered care and the robust research programs available at UT Southwestern. Originally from Houston, Texas, Dr. Qin holds a bachelor's degree in biological sciences and Asian studies from Rice University, where she graduated magna cum laude. She earned her medical degree from Baylor College of Medicine, and completed internal medicine residency training at Houston Methodist Hospital. She then gained advanced training through a hematology and medical oncology fellowship at the Icahn School of Medicine at Mount Sinai in New York. Certified by the Board of Internal Medicine, she joined the UT Southwestern faculty in 2021. Dr. Qin’s research interests include novel biomarkers, therapeutics, and therapeutic combinations in genitourinary cancers, particularly in the context of clinical trials. Dr. Qin is a member of the American Medical Association and the American Society of Clinical Oncology. She has published numerous academic articles and delivered several presentations. Personal Note Outside of medicine, Dr. Qin enjoys spending time with her family, exploring the great outdoors, and designing interior spaces. Education Medical School Baylor College of Medicine (2015) Internship Houston Methodist Hospital (2016) Residency Houston Methodist Hospital (2018), Internal Medicine Fellowship Icahn School of Medicine at Mount Sinai (2021), Hematology Oncology Research Interest Industy and Cooperative Group-sponsored Trials in Genitourinary Oncology Investigator-initiated Clinical Trials in Genitourinary Oncology Novel Biomarkers, Therapeutics, and Therapeutic Combinations in Genitourinary Oncology Publications Featured Publications Targeting HIF-2α in Renal Cell Carcinoma: Expanding upon Belzutifan. Rodriguez M, Qin Q, Tambar U, Brugarolas J. Cancer 2026 EXPLORE-RCC: a phase II study of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or inoperable clear cell renal cell carcinoma (ccRCC) Q. Qin, S. Zhang, J. Brugarolas, H. Hammers, C. Jiang, J. Vento, K. Courtney, S. Cole, M. McGuire, E. Hasanov, E.A. Singer, D.M. Geynisman, A. Kutikov, M.A. Reimers, K. Gaston, I. Tachibana, V. Margulis, J. Cadeddu, T. Zhang. ESMO Annual meeting 2025 A phase II study of niraparib (N), abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa; HARMONY) Qin Q, Jiang C, Song Zhang, Cole S, Courtney KD, Wang J, Arafat W, Vento J, Tawagi K, Reizine NM, Bilusic M, McGuire M, Rowell A, Wise DR, Reimers MA, Heath EI, Zhang T. ASCO Annual Meeting 2025 A Review of Neoadjuvant Therapy for Localized and Locally Advanced Renal Cell Carcinoma Qin Q, Tachibana I, Margulis V, Caddedu JA, Zhang T. Cancers 2025 Systemic Treatment of Locally Advanced or Metastatic Non-Clear Cell. Qin Q, Nein E, Flaten A, Zhang T. Cancers 2025 Durable Benefit from PARP Inhibitors in Metastatic Prostate Cancer in Routine Practice: Biomarker Associations and Implications for Optimal Clinical NGS Testing Triner D, Graf R, Madison R, Gjoerup O, Tukachinsky H, Ross J, Quintanilha J, Li G, Cheng H, Pritchard C, Zurita A, Qin Q, Zhang T, Agarwal N, Reichert Z, Mateo J, Cieslik M, and Morgan T. 2024 Phase 2 trial for sequential treatment after cabozantinib progression in metastatic renal cell carcinoma [Seq-Cabo] Qin Q, Hammers H, Brugarolas J, Arafat W, Courtney K, Zhang S, Cowey L, Hutson T, Zhang T. ASCO Annual Meeting 2024 Toxicity Management of Systemic Kidney Cancer Therapies. Qian Qin, Ellen Nein, Andrea Flaten, Tian Zhang. Hematol Oncol Clin North Am 2023 PD-L1 PET: A potential biomarker of checkpoint inhibitor sensitivity in renal cancer. Mulgoonkar A, Woolford L, Elias R, Guan KN, Hoo G, Stevens C, Tcheuyop VT, Haldeman S, Miyota J, Carrillo D, Qin Q, Singla N, Bowman I, Cadeddu J, Margulis V, Christie A, Kapur P, Pedrosa I, Dakanali M, Oz O, Sun X, Brugarolas J. AACR Annual Meeting 2022 Development of a novel HIF2a PET tracer: from proof of concept to a clinical trial. Debnath S, Stevens C, Brandenburg O, Sovich J, Gonzalez P, Qin Q, Haldeman S, Tcheuyap VT, Christie A, Thapa P, Zhou N, Mulgoonkar A, Hoo G, Miyata J, Carrillo D, Cadeddu J, Kapur P, Anderson J, Pedrosa I, Dakanali M, Oz O, Sun X, Brugarolas J. AACR Annual Meeting 2022 Results 1-10 of 20 1 2 Next Last Honors & Awards Eugene P. Frenkel, M.D., Endowed Scholar Award in Clinical MedicineUT Southwestern (2022) Second Place, Clinical Vignette Poster PresentationAmerican College of Physicians, Southeast Region (2016) Second Place, Research Poster PresentationAmerican College of Physicians, Southeast Region (2016) Professional Associations/Affiliations American Medical Association American Society of Clinical Oncology American Society of Hematology Caris Precision Oncology Alliance, Genitourinary Group Caris Precision Oncology Alliance, Genitourinary Group Chinese American Hematologist and Oncologist Network Dallas County Medical Society Eastern Cooperative Oncology Group, Genitourinary Working Group European Society of Medical Oncology Hoosier Cancer Research Network, Genitourinary Working Group Texas Medical Association
